<DOC>
	<DOCNO>NCT02561897</DOCNO>
	<brief_summary>This prospective randomize comparative evaluation Edoxaban Warfarin safety efficacy perioperative use patient non-valvular atrial fibrillation ( AF ) undergo clinically indicate implantation replacement cardiovascular implantable electrical devices.The primary objective compare rate local systemic bleeding subject randomize Edoxaban compare subject randomize continuous warfarin within 30 day cardiac rhythm device implant concomitant non-valvular AF .</brief_summary>
	<brief_title>EdoxabaN Warfarin Therapy In Cardiovascular Implantable Electrical Device Procedures Patients With Non-Valvular Atrial Fibrillation</brief_title>
	<detailed_description>This prospective randomize comparative evaluation Edoxaban Warfarin safety efficacy perioperative use patient non-valvular atrial fibrillation undergo clinically indicate implantation replacement cardiovascular implantable electrical device . This study randomize , open label , active-controlled trial open-label safety extension , design compare local systemic bleeding within 30 day cardiac rhythm device implant among subject randomize continuous Warfarin interrupt ( &lt; 24 hour ) Edoxaban . The study three phase , run phase establish stable warfarin therapy , acute open label 30 day phase subject randomize 1:1 ratio receive interrupt edoxaban continuous warfarin follow open label follow phase additional 5 month safety monitoring . Drug transition perform accord approve drug labeling .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Subjects establish atrial fibrillation ( AF ) bradycardia long term ( &gt; 3 week ) therapeutic oral anticoagulant ( OAC ) warfarin another OAC undergo new pacemaker system implant exist pacemaker system revision . Subjects newly detect bradycardia tachycardia syndrome AF recently ( less 3 week ) start warfarin , therapeutic international normalize ratio ( INR ) thrombus transesophageal echocardiogram ( TEE ) undergo new pacemaker system implant revision . Subjects AF ventricular tachyarrhythmias ( VT VF ) acquire structural heart disease candidate implantable cardioverterdefibrillator ( ICD ) therapy long term ( &gt; 3 week ) therapeutic OAC warfarin another OAC undergo new ICD system implant exist ICD system revision . Subjects newly detect AF VT VF recently ( less 3 week ) start warfarin , therapeutic INR thrombus TEE undergo ICD system implant revision Clinically significant valvular heart disease Subjects require cardiovascular implantable electrical device ( CIED ) lead extraction e.g . device site infection , endocarditis , lead advisory condition warrant lead ( ) system extraction . Recent ( &lt; 1 month ) myocardial infarction Documented leave atrial ( LA ) thrombus TEE Contraindications anticoagulant therapy adverse event prior warfarin edoxaban therapy Creatinine clearance &lt; 30ml/min &gt; 95 ml/min Hepatic disease , advance Recent stroke ( &lt; 3 month ) thromboembolic event Recent ( &lt; 3months ) intracranial major bleed event Use concomitant dual antiplatelet therapy oral , subcutaneous parenteral anticoagulant therapy Subjects warfarin without therapeutic INR level study entry Subjects clinically significant medical condition Subjects life expectancy &lt; 1 year Lead extraction procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>